Strong YoY growth, capex cuts signal moderation
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Met BioForLife timeline. Cut capex guidance without warning. YoY growth narrative (16.2%) conflicts with filed result (133%), raising transparency questions.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Viyash posted ₹988 Cr revenue with solid asset growth and BioForLife integration ahead, anchoring multi-year optionality. However, delivered results show 133% YoY growth but management highlighted only 16.2%—suggesting either quality-of-earnings concern or acquisition accounting. Capex cut from ₹250–300 to ₹140–150 Cr (40% reduction) signals moderation. Near-term caution (10% FY27 growth) conflicts with long-term ₹1B by FY32 (17–18% CAGR) thesis. Hold pending FY27 H2 visibility and capex rationalization.
₹987.9 Cr
Revenue · +133% YoY₹84.7 Cr
Reported PAT · +331.9% YoYCompressing
Margins · vs guidance: ContradictedDid the claims hold up?
Q2 FY27 revenue ₹988 Cr, up 16.2% YoY
MISSDelivered Q2 FY27 revenue ₹987.9 Cr, up 133% YoY per filed results
Q2 profit ₹85 Cr, up 16% YoY
MISSDelivered Q2 PAT ₹84.7 Cr, up 331.9% YoY
Gross margin 53.7% Q2, stable at 54–55% forward
OVERSTATEDDelivered gross margin not separately stated; NPM 8.5%, OPM 16.7%
Capex ₹140–150 Cr this year
METPrior guidance was ₹250–300 Cr; new guidance ₹140–150 Cr
Companion animal business at ₹20–30M, ~60% growth
OVERSTATEDDelivery numbers don't segment by companion vs farm animals; claim not independently verified
Earnings quality
What changed since the last call
Capex guidance slashed 40%
DowngradeFY27 capex cut from ₹250–300 Cr to ₹140–150 Cr. Animal health facility scaled back; strategy shifted to 'optimize capex' over next 2–3 years at ₹150 Cr.
BioForLife acquisition completed Oct 1
NewOn schedule per prior guidance. 100% stake acquired; consolidation from Q3 FY27. Opens geo-extension (Europe, emerging markets) and high-potency manufacturing.
API and companion animal growth tracking
NeutralAPI guidance reaffirmed 12–13% FY27 (vs prior 13–15%). Companion animal ₹30M (+60% YoY) now primary focus (up from ₹20M base last year).
U.S. business momentum slowdown
DowngradeExclusive product (CGT) generated $5M with 90%+ margin Q2 FY26; now ending. U.S. expected ₹480 Cr (15% YoY growth), lower than prior high-teens expectations.
The Q&A
Analysts pressed hard on U.S. business deceleration, capex cuts, gross margin volatility, and YoY growth slowdown. Management held firm on long-term strategy (animal health, 2029 patent expirations, ₹1B by FY32) but was defensive on near-term: attributed U.S. slowdown to one-time exclusive product, margins to war/input costs, and capex cut to 'optimization.' Tone confident but guarded on FY27 outlook (10% growth only).
U.S. business growth slowdown — Gourav Bhama, JM Financial
AnsweredOne exclusive product (CGT, $5M, 90% margin) ended after six-month window. Without exclusivity, U.S. base business normalizing; we expect ₹480 Cr (15% growth) for the year.
CDMO/API competition — Kenil Mehta, Boring AMC
PartialCDMO majority is farm animals (mature, differentiated). API working on strategic tie-ups; not at new chemical entity stage yet. We have 5-year visibility on most blockbuster products.
API growth trajectory & segment split — Anubhav Sangal, Anand Rathi
AnsweredAPI mid-teens (12–13%) FY27; companion animal $20–30M (60% growth); animal health ramped up 3x. We're at ₹30M companion now.
Emerging markets growth breakdown — Vishal Manchanda, Systematix
AnsweredBrazil 40% volume growth, Turkey good growth on new launches, Mexico stable. Strongest near-term expansion in Turkey and Brazil.
Gross margin drivers — Aman Goyal, IIFL
AnsweredWar-driven raw material inflation, solvent/price variance ~0.3–0.4%. Slight product mix change. Confident on 54–55% recovery forward through process efficiency.
Formulation vs API split & capex plan — Bharat Sheth, Quest
AnsweredFormulation will grow to 65–75% over 2–3 years via new products & acquisitions. Capex now ₹140–150 Cr this year (down from earlier ₹250–300 Cr); expect stable ₹150 Cr going forward.
U.S. generic market size & strategy — Chintan Modi, Oaklane
PartialEurope 50–60% generics now, expect 70–80% by 2029–2030. U.S. 15–20% generic opportunity; we target 15–20% market share in niche high-potency molecules.
Patent expirations & oncology R&D — Vishal Manchanda, Systematix
Answered2029 is major patent expiration year (₹3B+ market, 10 filings in advanced stage). Oncology center built; para IV products starting validation; expect material contribution FY30.
Carlyle stake & 20% growth feasibility — Kushal Goenka, Mangal Keshav
PartialCarlyle exploring exit next 12–15 months. We're confident on 20%+ growth. Infrastructure, R&D, strong balance sheet (net debt ₹26 Cr), and ₹1B FY32 target at 17–18% CAGR are achievable. Organic + inorganic.
Guidance
FY27 overall 10% growth (confidence level)
MediumPost-H1 momentum of 17.8% ease assumed. Near-term caution due to U.S. exclusivity wind-down and API demand headwinds (geopolitical).
API 12–13% FY27 (vs prior 13–15%)
MediumSlight cut from earlier range. Mid-teens is mid-term target pending patent expirations 2029+.
Companion animal ₹30M (~60% growth) FY27
HighAlready achieved ₹20–30M in H1; confidence high on 2029+ launches and geographic expansion.
Gross margin 54–55% FY27 forward
MediumQ2 at 53.7%; expect recovery via process efficiency, pricing actions, and product mix (animal health higher margin).
EBITDA margin ~21% (healthy from ESOP normalization)
HighH1 EBITDA margin 21.3% ex-ESOP. ESOP normalized Q1 FY28; expect stable 20–22% margin band forward.
FY27 capex ₹140–150 Cr (down from ₹250–300 Cr prior)
HighAnimal health facility (₹60 Cr spent; ₹60–80 Cr remaining). Optimization push; next 2–3 years ~₹150 Cr annualized.
FY28+ capex ₹140–150 Cr annualized, optimized
MediumPost-BioForLife integration and companion animal facility, capex expected to stabilize at lower run rate.
Risks the call surfaced
API market demand
HighWar-driven customer procurement delays and inventory normalization impacting API visibility. Q1 demand weak; Q2 recovery partial.
Gross margin sustainability
MediumQ2 gross margin 53.7% vs 55.5% prior year. War-driven raw material inflation and solvent price volatility cited. Recovery to 54–55% assumed but not guaranteed.
U.S. business slowdown
MediumU.S. exclusive product (CGT, $5M, 90% margin) ended H1. Base U.S. business expected ₹480 Cr (15% growth) vs high-teens prior. Generics at 15–20%, expected to reach 70–80% by 2029–2030 in Europe.
Capex cut implications
MediumCapex cut from ₹250–300 Cr to ₹140–150 Cr (40% reduction). Companion animal facility commissioning Q1 FY28; delay risk. Animal health R&D expansion may slow.
Patent expiration timing risk
MediumMajor patent expirations 2029 open ₹3B+ market. 20+ filings in advanced stages. Delays in regulatory approvals (FDA, EMA) could push revenue contribution to 2030 or later.
Quality of earnings
HighManagement highlighted 16.2% YoY revenue growth in call. Delivered result shows 133% YoY. Likely acquisition accounting or prior-year restatement not disclosed. Raises transparency concerns.
Management
Score 7/10. Detailed and strategic on long-term roadmap (animal health, patent expirations, new product launches). Transparent on headwinds (war impact, margin pressure, U.S. slowdown). However, communication gap: highlighted 16.2% growth while filed result is 133%, raising clarity concerns. Complex explanations sometimes obscure the main narrative. Met BioForLife acquisition timeline (Oct 1). Animal health R&D tripled and showing 60% companion animal growth. Companion animal facility on track Q1 FY28. However, capex cut from ₹250–300 to ₹140–150 Cr (40%) without prior warning signals moderation or execution risk on growth plans.
1 · Q1 FY28
Companion animal facility commissioning; BioForLife full consolidation
2 · 2028–2029
First wave of major new product launches (20+ filings in advanced stages)
3 · 2029 onwards
Patent expirations open $3B+ market opportunity; generic entry possible
Hold pending FY27 H2 visibility and capex rationalization.
Informational and educational content only. Not investment advice.